The Food and Drug Supervisory Agency (BPOM) said that biological products have dominated the global market, with biological medicines covering 65 percent, and some of these are medical products for advanced therapy which are expected to become a trend.
Head of the POM Taruna Ikrar stated that medical products for advanced therapy (advanced therapy medicinal products) holds great hope for a cure through scalable, precise, and persistent treatment. He quoted from the World Health Organization (WHO), the trend of diseases has changed, from the majority being infectious to non-infectious.
“According to the world average, 71 percent of deaths are caused by non-infectious diseases. Meanwhile in Indonesia, it is even much greater, 73 percent of deaths in Indonesia are caused by non-infectious diseases,” he said in a broadcast in Jakarta, Monday. .
Also read: Maturity of Pharmaceutical Companies Needs to Be Increased to Lower Drug Prices on the Market
He explained that medical products for further therapy include products based on cell therapy, genetic therapy and tissue engineering. According to him, such biological products are not like synthetic drugs, which only cure symptoms.
“If his blood pressure is high, how can he be given chemicals that can either stick to his alpha or beta receptors, or beta blockers, to lower his blood pressure. But that’s symptomatic, not curative,” he said as an example.
Because of this, he said, patients end up dependent until the end of their lives. According to him, this has an impact on the economy, where the majority of funding is disbursed to treat non-infectious diseases.
Also read: Increase Routine Supervision to Avoid Drug Contamination Impact of GGAPA Case Verdict
Taruna believes there is a huge opportunity for investment and research to develop biological products.
“But we are still struggling to carry out research, because science is still developing. That’s the first thing. Second, in the context of what we call a business plan, it’s time for companies to invest in this field, don’t be late,” he said.
He explained that currently in Indonesia there are only four companies that have received Good Medicine Manufacturing Practices (CPOB) certificates for this therapy cell.
Therefore, his party is committed to developing this knowledge, by inviting stakeholders such as companies, industry, academics and the public to help achieve this. (Ant/D-2)
#POM #Medicine #Advanced #Therapy #Estimated #Trend
